Johnson & Johnson Innovation – JJDC, Inc.

About us

Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. Our portfolio companies benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation.

Strategic

JJDC 2018 Newsletter

2018 marks an important milestone for JJDC as we celebrate our 45th anniversary as strategic investors for the Johnson & Johnson Family of Companies.

Click here to view newsletter

JJDC finds transformative ideas and helps them mature into real solutions for today’s patients.

Guided by a clear, consistent investment strategy aligned with scientific goals, JJDC works hand-in-hand with partners to navigate the path to creating breakthrough health innovations.

We invest across sectors—pharmaceuticals, medical devices and consumer healthcare—and at all stages, from seed-level startups to Series B and beyond.

All of our portfolio companies receive the same unwavering commitment. We take a long-term approach, deploying the full capabilities of the Johnson & Johnson family of companies, including discovery, clinical development, regulatory affairs, manufacturing and commercialization.

Our team includes leaders in the healthcare and technology communities, many with deep R&D experience. This gives us the ability to understand our partners and provide the help they need.

Every opportunity is unique, with tailored roles and terms that provide the best path to success.

Team

Approach

We’re positively impacting human health through innovation. To do this, we identify the best opportunities across all sectors and allow innovators to leverage Johnson & Johnson’s many resources.

We’ve Been There Before

Our highly experienced team hails from throughout the healthcare and technology venture communities, many of us bringing deep R&D experience in addition to investment acumen. Just like you, we are entrepreneurs, scientists and studied risk-takers. Our team’s unique vantage point gives us an exceptional ability to understand the challenges and provide the right kind of help at the right time.

Investing With Impact

We have dedicated teams focused on investing at all stages of innovation, and across all four sectors: pharmaceuticals, medical devices, consumer health and global public health. We seek innovations with potential to make a transformational impact in the health and lives of people around the globe.

If your early-stage company is looking to advance a program that is pre-proof of concept in humans, connect with one of our Johnson & Johnson Innovation Centers, located around the globe in the life science hot spots of Asia Pacific, Boston, California and London.

Each Investment Is Unique

At JJDC, there’s no such thing as a one-size-fits-all approach. We understand that each idea is unique, requiring an equally distinct investment strategy. We customize every deal to the opportunity, ranging from Seed and Series A investments in the earliest-stage startups to Series B investments and beyond in more mature companies. We also make private investments in public equity.

Creating Thriving Enterprises

For more than 40 years, JJDC has made investments in hundreds of innovative companies across pharmaceuticals, medical devices and consumer healthcare. Once we invest, we’re committed to you. We believe in value-add investing, playing an active role in providing strategic direction and enabling access to internal experts across the Johnson & Johnson Family of Companies.

Focus Areas

JJDC is seeks ideas that align with our business priorities in our Pharmaceuticals, Consumer and Medical Devices sectors. In each sector, we focus on specific therapeutic areas of interest that have the greatest potential to improve the lives of patients and consumers.

CLICK a business area of interest below

Consumer
Medical Devices
Pharmaceuticals
Global Public Health

CLICK on a circle to see the areas we are targeting

Healthy Sleep Habits, Massage and Sensory Enrichment, Safe Bug Care Products, Environmental Skin Protection (Germs, Sun, Pollution), Ease of Use Solutions

Baby Care

Baby Care
Skin, Acne, Blackheads, Oily Skin, Aging Prevention, Environmental Protection, Sunscreen Compliance and Sensory Experience, Body hydration and skin barrier protection, Therapeutic Hair Care, Novel Hair Growth Solutions

Beauty

Beauty
Bug Bites, Burns, Cracked Skin, Instant, Long-Lasting Pain Relief, Infection Reduction, Protection, Accelerate & Monitoring Healing, Ease of Use Solutions

Compromised skin

Compromised skin
Novel Solutions for Feminine Hygiene, Fit and Comfort, Discretion, Health Sensing & Promoting

Feminine Personal Care

Feminine Personal Care
Enamel Repair, Microbial Control for Prevention of Oral Conditions, Functional Barriers for Tooth Protection, Whitening Technologies, Oral Health Sensing

Oral Care

Oral Care
Pain: Episodic and Recurrent Head and Body Pain,
Cough & Cold: Multi-symptom Head Cold, Cough and Sore Throat,
Digestive Health: IBS, Diarrhea, Constipation, Indigestion, Dehydration, Heartburn,
Allergy: Episodic Respiratory, Skin/Atopic, and Food Allergies,
Smoking Cessation: Nicotine replacement therapy, non-nicotine drugs, devices, behavioral programs

OTC

OTC

JJI-JJDC News

05/23/2019

GCV Powerlist 2019: #23 Tom Heyman

01/31/2019

GCV Rising Stars Awards 2019: #4 Marian Nakada

05/21/2018

GCV Powerlist 2018: #5 Tom Heyman

03/28/2018

Big Pharma’s Billion-Dollar Scramble to Invest in Start-ups to Fuel Innovation

01/31/2018

Global Corporate Venturing Rising Stars Awards 2018: #8 Stacy Feld

Portfolio Company News

06/26/2019

DayTwo Secures $31 Million In Series B Financing To Scale Microbiome Research Platform To Address Chronic Health Conditions

05/21/2019

Cala Health Raises $50 Million Series C Funding

05/13/2019

Zebra Medical Vision Receives FDA Approval for World's First AI Chest X-ray Triage Product

04/08/2019

HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing

04/01/2019

BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140

Contact

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

contact